2022
Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells.
McBrearty N, Cho C, Chen J, Zahedi F, Peck A, Radaelli E, Assenmacher C, Pavlak C, Devine A, Yu P, Lu Z, Zhang H, Li J, Pitarresi J, Astsaturov I, Cukierman E, Rustgi A, Stanger B, Rui H, Fuchs S. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Molecular Cancer Research 2022, 21: 228-239. PMID: 36378658, PMCID: PMC9992122, DOI: 10.1158/1541-7786.mcr-22-0602.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinoma, Pancreatic DuctalHumansMiceMice, KnockoutPancreatic NeoplasmsSteroid HydroxylasesConceptsPancreatic ductal adenocarcinomaPancreatic cancer cellsPDAC cellsCH25H expressionTumor growthT cell tumor infiltrationMouse PDAC cellsImmune checkpoint inhibitorsCancer cellsDownregulation of MHCPancreatic intraepithelial neoplasiaImmune-competent hostsHuman pancreatic cancerPotential translational importanceAccumulation of cholesterolCheckpoint inhibitorsIntraepithelial neoplasiaPoor prognosisTumor infiltrationPancreatic cancerDuctal adenocarcinomaTherapeutic approachesCH25HTumor progressionCholesterol deficit
2021
Regulation of intercellular biomolecule transfer–driven tumor angiogenesis and responses to anticancer therapies
Lu Z, Ortiz A, Verginadis I, Peck A, Zahedi F, Cho C, Yu P, DeRita R, Zhang H, Kubanoff R, Sun Y, Yaspan A, Krespan E, Beiting D, Radaelli E, Ryeom S, Diehl J, Rui H, Koumenis C, Fuchs S. Regulation of intercellular biomolecule transfer–driven tumor angiogenesis and responses to anticancer therapies. Journal Of Clinical Investigation 2021, 131: e144225. PMID: 33998600, PMCID: PMC8121529, DOI: 10.1172/jci144225.Peer-Reviewed Original ResearchConceptsTumor growthEndothelial cellsMetastatic diseaseAnticancer therapyPoor disease outcomeColorectal cancerIntratumoral angiogenesisAngiostatic effectsDisease outcomeTherapeutic effectSide effectsOverall efficacyPharmacologic inhibitionTumor angiogenesisCH25HTherapyBenign cellsAngiogenesisDiseaseLow levelsCellsRegimensPatientsReserpineCancer
2019
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles
Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY. An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell 2019, 35: 33-45.e6. PMID: 30645975, PMCID: PMC6336114, DOI: 10.1016/j.ccell.2018.12.001.Peer-Reviewed Original ResearchConceptsTumor-derived extracellular vesiclesMelanoma lung metastasisPre-metastatic nicheLung metastasesAdjuvant melanoma therapyAnti-hypertensive drugsUse of reserpineExtracellular vesiclesType I interferon receptorMelanoma patientsPoor prognosisCH25HMelanoma therapyIFN receptorInterferon receptorMetastasisNormal cellsHealthy cellsReceptorsUptakeCellsPatientsPrognosisReserpineTherapy